Gerresheimer reported preliminary first-half 2026 earnings before interest, taxes, depreciation and amortisation of €168 million, down from €210.4 million a year earlier. The German drug-packaging maker said weakness in its Moulded Glass business and lower demand for injection vials weighed on performance. The figures were reported on Sept. 30.